心力衰竭中毛细血管后肺动脉高压:PH-HF多中心研究对当前定义影响的解读
该前瞻性多中心研究纳入662例需右心导管检查的稳定左心衰患者,评估2022年欧洲指南下调平均肺动脉压和肺血管阻力阈值对毛细血管后肺动脉高压患病率及预后的影响。结果显示下调平均肺动脉压阈值使患病率增加10%,下调肺血管阻力阈值使合并型毛细血管后肺动脉高压增加60%,且平均肺动脉压和肺血管阻力均与主要终点独立相关。
要点
- 2022年定义下调平均肺动脉压阈值使毛细血管后肺动脉高压患病率增加10%。
- 下调肺血管阻力阈值使合并型毛细血管后肺动脉高压患病率增加60%。
- 平均肺动脉压>20 mmHg和肺血管阻力>2 WU对心衰患者具有预后价值。
核心结论
- 本研究首次强调新毛细血管后肺动脉高压定义对合并型毛细血管后肺动脉高压患病率的影响,并验证平均肺动脉压>20 mmHg和肺血管阻力>2 WU在心衰患者中的预后价值。
研究设计与样本
- 前瞻性多中心研究,纳入2010至2018年需右心导管检查的稳定左心衰患者662例,中位年龄63岁,男性60%。
主要发现
- 平均肺动脉压阈值从25降至20 mmHg使毛细血管后肺动脉高压患病率增加10%。
- 肺血管阻力阈值从3降至2使合并型毛细血管后肺动脉高压患病率增加60%,主要终点净重分类改善显著。
- 与主要终点相关的最佳肺血管阻力阈值约为2.2 WU。
关键数值与推荐
- 2022年欧洲指南将毛细血管后肺动脉高压的平均肺动脉压阈值从25 mmHg降至20 mmHg,肺血管阻力阈值从3降至2。
临床怎么用
- 在心衰患者中采用2022年定义评估毛细血管后肺动脉高压可识别更多合并型患者,平均肺动脉压>20 mmHg和肺血管阻力>2 WU具有预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). However, the impact of this definition and its prognostic value has never been evaluated prospectively. METHODS: Stable left HF patients with the need for right heart catheterization were enrolled from 2010 to 2018 and prospectively followed up in this multicentre study. The impact of the successive pcPH definitions on pcPH prevalence and subgroup [i.e. isolated (IpcPH) vs. combined pcPH (CpcPH)] was evaluated. Multivariable Cox regression analysis was used to assess the prognostic value of mPAP and PVR on all-cause death or hospitalization for HF (primary outcome). RESULTS: Included were 662 HF patients were (median age 63 years, 60% male). Lowering mPAP from 25 to 20 mmHg resulted in +10% increase in pcPH prevalence, whereas lowering PVR from 3 to 2 resulted in +60% increase in CpcPH prevalence (with significant net reclassification improvement for the primary outcome). In multivariable analysis, both mPAP and PVR remained associated with the primary outcome [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.00-1.03, P = .01; HR 1.07, 95% CI 1.00-1.14, P = .03]. The best PVR threshold associated with the primary outcome was around 2.2 WU. Using the 2022 definition, pcPH patients had worse survival compared with HF patients without pcPH (log-rank, P = .02) as well as CpcPH compared with IpcPH (log-rank, P = .003). CONCLUSIONS: This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP > 20 mmHg and PVR > 2 WU among HF patients.
引用
- Fauvel, Damy, Berthelot, et al. Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study. Eur Heart J. 2024. PMID: 39056467. doi:10.1093/eurheartj/ehae467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。